Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online
VJOncology avatar; VJ Oncology @VJOncology ·
April 19, 2024 1781291779913826750

Missing #AACR24? 🧬

…us too!

For exclusive coverage, interviews and all the latest in #Oncology visit us at 👉 http://VJOncology.com 👈

@AACR #oncology

Image for the Tweet beginning: Missing #AACR24? 🧬 …us too! For exclusive Twitter feed image.
Reply on Twitter 1781291779913826750 Retweet on Twitter 1781291779913826750 0 Like on Twitter 1781291779913826750 0 Twitter 1781291779913826750
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780980922059264126

🎥We had the privilege of talking to @CharlesSwanton on the #BTOG24 keynote lecture surrounding the initiation of #lungcancer in response to the inhalation of air pollution

👀Interview coming soon to http://VJOncology.com - watch this space!

@BTOGORG #LCSM #NSCLC @TheCrick

Image for the Tweet beginning: 🎥We had the privilege of Twitter feed image.
Reply on Twitter 1780980922059264126 Retweet on Twitter 1780980922059264126 2 Like on Twitter 1780980922059264126 14 Twitter 1780980922059264126
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780967192143536202

🎥We were delighted to catch up with @cpeedell on #lungcancer updates at #BTOG24 including whether there is a role for radiotherapy in extensive-stage #SCLC

👉Full interview coming soon to http://VJOncology.com

@BTOGORG #LCSM #NSCLC #LungCancer

Image for the Tweet beginning: 🎥We were delighted to catch Twitter feed image.
Reply on Twitter 1780967192143536202 Retweet on Twitter 1780967192143536202 3 Like on Twitter 1780967192143536202 6 Twitter 1780967192143536202
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780906710992842782

🎥We had the pleasure of catching up with @AdamJanuszewski this morning to discuss the BTOG Therapeutics Symposium, ADCs in #lungcancer, and more at #BTOG24

👀Interview coming soon to http://VJOncology.com

@BTOGORG #LCSM #NSCLC #SCLC #LungCancer

Image for the Tweet beginning: 🎥We had the pleasure of Twitter feed image.
Reply on Twitter 1780906710992842782 Retweet on Twitter 1780906710992842782 2 Like on Twitter 1780906710992842782 4 Twitter 1780906710992842782
Load More

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online
The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos
VJOncology avatar; VJ Oncology @VJOncology ·
April 19, 2024 1781291779913826750

Missing #AACR24? 🧬

…us too!

For exclusive coverage, interviews and all the latest in #Oncology visit us at 👉 http://VJOncology.com 👈

@AACR #oncology

Image for the Tweet beginning: Missing #AACR24? 🧬 …us too! For exclusive Twitter feed image.
Reply on Twitter 1781291779913826750 Retweet on Twitter 1781291779913826750 0 Like on Twitter 1781291779913826750 0 Twitter 1781291779913826750
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780980922059264126

🎥We had the privilege of talking to @CharlesSwanton on the #BTOG24 keynote lecture surrounding the initiation of #lungcancer in response to the inhalation of air pollution

👀Interview coming soon to http://VJOncology.com - watch this space!

@BTOGORG #LCSM #NSCLC @TheCrick

Image for the Tweet beginning: 🎥We had the privilege of Twitter feed image.
Reply on Twitter 1780980922059264126 Retweet on Twitter 1780980922059264126 2 Like on Twitter 1780980922059264126 14 Twitter 1780980922059264126
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780967192143536202

🎥We were delighted to catch up with @cpeedell on #lungcancer updates at #BTOG24 including whether there is a role for radiotherapy in extensive-stage #SCLC

👉Full interview coming soon to http://VJOncology.com

@BTOGORG #LCSM #NSCLC #LungCancer

Image for the Tweet beginning: 🎥We were delighted to catch Twitter feed image.
Reply on Twitter 1780967192143536202 Retweet on Twitter 1780967192143536202 3 Like on Twitter 1780967192143536202 6 Twitter 1780967192143536202
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780906710992842782

🎥We had the pleasure of catching up with @AdamJanuszewski this morning to discuss the BTOG Therapeutics Symposium, ADCs in #lungcancer, and more at #BTOG24

👀Interview coming soon to http://VJOncology.com

@BTOGORG #LCSM #NSCLC #SCLC #LungCancer

Image for the Tweet beginning: 🎥We had the pleasure of Twitter feed image.
Reply on Twitter 1780906710992842782 Retweet on Twitter 1780906710992842782 2 Like on Twitter 1780906710992842782 4 Twitter 1780906710992842782
Load More

Late-Breaking Abstracts at ASCO 2022!

View all
1:28
PARADIGM: panitumumab superior to bevacizumab as 1L treatment of patients with RAS WT mCRC
Takayuki Yoshino • 5 Jun 2022
2:19
Final results from ATLANTIS cabozantinib arm for urothelial carcinoma
Robert Jones • 4 Jun 2022
1:22
KRYSTAL-1: activity and safety of adagrasib in patients with advanced/metastatic KRASG12Cm NSCLC
Alexander Spira • 3 Jun 2022
5:11
DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBC
Hope Rugo • 5 Jun 2022

Latest videos from ASCO 2022

View all
1:13
Promising future of PSMA for prostate cancer
Eugene Shenderov • 10 Jun 2022
6:57
Phase II trial of enoblituzumab for patients with intermediate/high-risk localised prostate cancer
Eugene Shenderov • 10 Jun 2022
1:42
Next-generation ALK inhibitors: treatment sequencing and resistance
Alessandra Bearz • 6 Jun 2022
1:17
MK-0482-001: evaluating MK-0482 plus pembrolizumab in patients with advanced solid tumors
Andre Goy • 5 Jun 2022

Breast Cancer at ASCO 2022

View all
3:01
Assessing elacestrant in ctDNA-positive patients with ER+ breast cancer
Thomas Meyskens • 30 May 2022
4:29
Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancer
Thomas Meyskens • 30 May 2022
2:35
AMEERA-6: Amcenestrant, a novel SERD, in HR+ breast cancer
Thomas Meyskens • 30 May 2022
1:08
DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancer
Thomas Meyskens • 30 May 2022

GU at ASCO 2022

View all
1:13
Promising future of PSMA for prostate cancer
Eugene Shenderov • 10 Jun 2022
6:57
Phase II trial of enoblituzumab for patients with intermediate/high-risk localised prostate cancer
Eugene Shenderov • 10 Jun 2022
1:59
Next steps for belzutifan for Von Hippel-Lindau syndrome
Ramaprasad Srinivasan • 17 Jun 2022
13:17
Belzutifan for Von Hippel-Lindau syndrome
Ramaprasad Srinivasan • 17 Jun 2022
The content of VJOncology is intended for healthcare professionals